Gamida Cell (Gamida Cell) Interest Expense : $-23.80 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Gamida Cell Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gamida Cell's interest expense for the three months ended in Dec. 2023 was $ -9.54 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.80 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gamida Cell's Operating Income for the three months ended in Dec. 2023 was $ -16.22 Mil. Gamida Cell's Interest Expense for the three months ended in Dec. 2023 was $ -9.54 Mil. Gamida Cell did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gamida Cell Interest Expense Historical Data

The historical data trend for Gamida Cell's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gamida Cell Interest Expense Chart

Gamida Cell Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.76

-0.65

-2.63

-5.68

-7.59

Gamida Cell Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-3.53	-1.38	-12.87	-	-9.54

Gamida Cell Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.80 Mil.

Gamida Cell (OTCPK:GMDAQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gamida Cell's Interest Expense for the three months ended in Dec. 2023 was $-9.54 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-16.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $75.17 Mil.

Gamida Cell's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Gamida Cell did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Gamida Cell (Gamida Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gamida Cell Ltd (OTCPK:GMDAQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116

Website

https://www.gamida-cell.com

Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.

Executives

Jeremy Blank	director	6446 DREXEL AVENUE, LOS ANGELES CA 90048
Mary Theresa Coelho	officer: Chief Financial Officer	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Ronit Simantov	officer: CMO & Chief Scientific Officer	1988 CHAPEL STREET, NEW HAVEN CT 06515
Abigail L. Jenkins	director, officer: President and CEO	C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116
Stephen T Wills	director	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ivan M. Borrello	director	C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Anat Cohen-dayag	director	C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Naama Halevi-davidov	director	C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003
Joshua F. Patterson	officer: General Counsel	C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bio Medical Investment (1997) Ltd.	other: Affiliate of 10% Owner	3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301
Shai Lankry	officer: Chief Financial Officer	C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Ai Gamida Holdings Llc	other: Affiliate of 10% Owner	40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ofer Gonen	director	1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Clal Biotechnology Industries Ltd.	other: Affiliate of 10% Owner	3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik	10 percent owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019